论文信息 - A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida) - 字舞流文

A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)

D. Amadori | M. Moroni | N. Ibrahim | Jenny C. Chang | M. Wicha | G. Viale | P. Pedrazzoli | M. Campone | A. Mruk | P. Morandi | P. Tomczak | E. Starosławska | M. Wojtukiewicz | L. Goldstein | M. Colleoni | F. Duhoux | J. Ferrero | L. Biganzoli | M. Graham | L. Venat-Bouvet | A. Gonçalves | A. Schott | M. Šmakal | M. Huizing | S. Cinieri | S. Henry | C. Lévy | R. Alvarez | A. Zelnak | J. Prausová | J. Medioni | M. Abu-Khalaf | J. Comer | P. Ruffini | D. Verhoeven | M. Jiménez | M. Kohoutek | E. Kubala | M. Zimovjanová | V. Richard | B. Kukiełka-Budny | H. S. Parra | M. Meshad | T. Sarosiek | M. Mansutti | I. Fernández-Pérez | Beth Butler | S. Mccanna | Ricardo H. Anne F. Maysa Nuhad Brooke Michael David Amelia Alvarez Schott Abu-Khalaf Ibrahim Daniel | B. Daniel | D. Kanamori | M. Krásenská | S. A. Novoa | Estela Vega Alonso | M. Zimovjanova